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ABSTRACT 
Correlates of Antidepressant Medication 
Compliance Use Among Depressed Women 
by 
Pamela Linton, Master of Science 
Utah State University, 2001 
Major Professor: Dr. Scot Allgood 
Department: Family and Human Development 
Medication compliance/no ncompliance was examined in context of: severity of 
symptoms; medical side effects; medication education; perceived stigma; and effects on 
family/soc ial support system. A null hypothesi s was formulated for each correlate, 
stating that those patients who reported a high level of an independent variable (IV) 
ttl 
would not be any more likely to discontinue their medication tban patients who reported a 
lew level of an IV. To obtai a data, a medical usage questionnaire and a depressior, 
assessment (OQT"-45.2) were used. Statistical significance was not obtained for any of 
the hypothesized relationships but trends were cons istent with the established literature. 
The impl ication points to the efficacy of relational therapy as a conjunct to the medical 
treatment of depression. 
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CHAPTER I 
INTRODUCTION 
Physicians report that female patients, diagnosed with depression, often 
discontinue their antidepressive medications spontaneous ly, translating into prolonged 
problems for the women. Noncompliance with the physician's prescription is a problem 
because the depression returns and the medication process has to start over again 
(Munizza, Tibaldi, Bollini , Pirfo, & Punzo, 1995). Patients may not be aware that 
spontaneous discontinuation of antidepressive medication can cause an increase in 
depression due to reduction of a therapeutic level of medication (Munizza eta!.). 
The severity of depression acts as a cata lyst in medication compliance because of 
the associated complications of symptoms (Bhatia & Bhatia, 1997). Because depression 
is a major problem in this country, studies are necessary to understand more about the 
nature of depression and medication compliance (Coyne, 1987; Hirschfeld, 1994). 
Depression of an individual also impacts his or her family. Marriage relationships 
influence and are influenced by depression (Coyne, 1987). However, tbe side effects of 
antidepressant medication may impact the marital relationship if, for example, the woman 
is dealing with decreased libido or unwanted weight gain (Jensvold, Plaut, Rojansky, 
Crenshaw, & Halbreich, 1996; Shen & Hsu, 1995) or decreased emotional responsi vity. 
Thus, the immediate side effects of the medication may be a strong deterrent to 
medication compliance. 
Research suggests that medication compliance is low when the patient receives 
inadequate infom1ation about the antidepressant medication from the prescribing doctor 
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and the pharmacist (Crenshaw & Goldberg, 1996). Many physicians and pharmacists 
realize that they should take time to educate patients about medication use, 
pharmacology, and side effects. Research has shown that there are specific ways that 
those topics can be approached with female patients so that maximum benefit can result 
(Blechman & Brownell , 1988; Crenshaw & Goldberg, 1996; Jensvold et al. , 1996; 
Sorvaniemi, Joukamaa, Helen ius, & Salokangas, 1996). Thus , education about the 
medication is clearly linked to compliance; that is, compliance is greater when the patient 
is fully informed about the medication. 
Some women report to their primary care physicians that husband and family are 
concerned about the stigma or the embarrassment of having their wife or mother treated 
for depression (L. Eskelson, personal communication, March, 5, 1998; R. Wortham, 
personal communication, December l , 1998). [n addition, many women also worry what 
others in their larger support system will think of them (M. Gibby, personal 
communication , May 7, 1998). To alleviate the concerns patients feel about the stigma of 
having depression, they may discontinue treatment by discontinuing their medication. 
The concern about stigma may be greater than the concern about medication compliance. 
Purpose 
The purpose of this study was to investigate compliance or noncompliance 
(discontinuation) with antidepressant medication prescription in context of severity of 
symptoms, medical side effects, medication education, perceived stigma, and effects on 
family/soc ial support system. 
Conceptual Framework 
To investigate compliance or noncompliance with antidepressant medication 
prescription in context of selected correlates, an overarching framework of human 
behavior must be integrated into the study. By broadening the lens of human behavior, 
assumptions can be made within a framework that accounts for behavior. According to 
Symbolic Interaction theorists, all meaning comes from interpretations that people attach 
to their interactions with one another (LaRossa & Reitzes, 1993). Everyday interactions, 
historical events, culture, and societal norms all influence individuals and prompts their 
motives and behavior (LaRossa & Reitzes). For some susceptible individuals, negative 
meaning attached to certain interactions may res ult in the development of depressive 
symptoms. Meaning is also derived concerning motivations to stay in compliance with 
prescribed antidepressant medication or to discontinue medication. 
Symbolic interactionism (Sl), within the context of general systems theory 
(GST), merges two dynamic theories to account for much human behavior. The following 
GST constructs (using the terminology of Gregory Bateson, considered the father of 
systems theory, and Ludvig von Bertalanffy) del ineate ways we may order our world 
(Goldberg & Goldberg, 1980; Whi techurch & Constan tine, 1993). Nonsummativity is 
another word for synergy, the concept that a system (nations, communities, families, 
couples, or an individual) is greater than the sum of its parts (Whitechurch & 
Constantine). This concept underlies the belief that compliance or noncomp li ance with 
antidepressant medication must be explored not only on an individual level but in light of 
interconnections with the family and the social support systems. 
3 
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Cybernetics theory suggests the idea that systems are self-regulating (Goldberg & 
Goldberg, 1980; Guttman, 1991 ). Self-regulation is accomplished through change within 
the system, which occurs through the process of feedback loops (Goldberg & Goldberg; 
Guttman). Positive feedback initiates a second order change-- e.g., the individual takes 
information and processes it to change from the original meaning that he or she had. 
When the feedback results in a negative feedback loop, the individual will use that 
information to reinforce previous beliefs (Goldberg & Goldberg; Guttman). 
Self-regulation, through the process of feedback loops, is critical to understand in 
connection with compliance or noncompliance with medication. Medication education 
and perceived stigma (two of the correlates of compliance or noncompliance with 
medication) are critically influenced by self-regulation. For a patient to assimilate 
medical education, a positive feedback loop may have to be processed to stay in 
compliance with medication prescription. In other words, if patient perception of 
antidepressant medication does not match the doctor's perception, she must change her 
way of thinking to stay in compliance with mediation prescription. 
Concerning stigma, if patients continue in a negative feedback loop, they may 
reinforce their previous beliefs about st igma. In other words, if a patient believes there is 
a stigma attached to antidepressant medication use, she will use that information to 
reinforce her belief. As an individual communicates with other systems, all information 
is processed through the unique lens of the individual. The "other systems" of concern in 
this study are family members, friends, health practitioners, and psychotherapists. 
Important parts of communication are the report (actual information) and command 
( interpretation) concepts (Guttman, 1991). In any communication one cannot be sure 
that the information sent to another is interpreted as it was intended. 
Communication about each of the correlates of antidepressant compliance or 
noncompliance is vital. For instance, the information an individual processes about 
medical side effects and severity of symptoms may result in actions that will either 
promote compliance or noncompliance with antidepressant medication. It is necessary to 
communicate with all the appropriate systems to attain as much consensus in meaning as 
possible (Guttman, 1991). The research focus of this study, compliance or 
noncompliance with antidepressant medication in the context of the correlates (severity 
of symptoms, medica l side effects, medication education, perceived stigma, and effects 
on family/socia l support system) was investigated from the perspective of SI and GST. It 
is also important to investigate the communication concerning the con·elates. 
CHAPTER II 
REVIEW OF LITERATURE 
6 
Although there is no consensus of the definition and cause of depression, there are 
recognized correlates to the use of antidepressant medication. Five areas of concern are 
connected to the research on antidepressant medication use among women. First, the 
severity of the symptoms of depression is a factor that often determines use or nonuse of 
medication. Second, medication discontinuance may be tied into the dynamics of a 
woman's fam ily and social support system, which are profoundly impacted by her 
depression. Third, the negative side effects from use of antidepressant medication vary 
widely and may be compounded by other medical problems. Fourth, if the patient does 
not have a basic understanding of the chemistry and function of antidepressant 
medication, she will not realize the gravity of proper medication use. Finally, the social 
stigma that is still attached to depression is such a powerful deterrent to acknowledging 
depression that its role as a correlate in antidepressant use cannot be ignored. Thus, 
patient cooperation with medication treatment may decrease as risks and side effects 
increase. Depression and corre lates of the use of antidepressant medication are further 
discussed in the following review. 
Depression 
Millon and Everly ( !985) defined depress ion as the decompensation of normal 
personality patterns. Nom1al personality patterns are the deeply embedded and broad ly 
exhib ited cognitive, affective, and overt individual behavioral traits that are constant over 
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time and are difficult to extinguish (Mi llon & Everly). The criteria for a major depressive 
episode, as described in the Diagnostic and Statistical Manual of Mental Disorders (41h 
edition; DSM-IV), are five or more of the following symptoms that have persisted for a 
2-week period and must include either symptom# I or #2: 
l. Depressed mood most of the day, nearly every day 
2. Diminished interest or pleasure in almost all activities nearly every day 
3. Significant weight loss or gain or decreased or increased appetite nearly daily 
4. Insomnia or hypersomnia nearly every day 
5. Psychomotor agitation or retardation nearly every day 
6. Fatigue or loss of energy nearly every day 
7. Feelings of worthlessness or excessive or inappropriate guil t nearly every day 
8. Diminished ability to think or concentrate, or indecisiveness , nearly every day 
9. Recurrent thought of death, recurrent suicida l ideation, or suicide attempt or specific 
suicide plan 
The symptoms of depression must also include a clinically significant distress or 
impairment in soc ial , occupational , or other important areas of functioning and the 
symptoms cannot be attributed to bereavement, namely, recent loss of a loved one 
(American Psychiatric Association , 1994). 
A hallmark symptom of depression that may be manifest in all of the above noted 
symptoms is cogni tive rigidity, or the tendency to focus in an ali-or-nothing thought 
process (Beck, Ward, Mendelson, Mock, & Erbaugh, 196 1 ). Cognitive rigidity generally 
results in distorted thinking, locking thought processes into worst case scenarios-thereby 
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reinforcing the previously mentioned symptoms. 
Blechman and Brownell ( 1988) noted that several classes of clinical depression 
included the following factors: genetic, biological, stage of female reproductive cycle, 
and social/psychological , which include gender roles and cognitive distortion. Given the 
gender specificity of some of these factors, it is not surprising that more women are 
diagnosed with depression than men (American Psychiatric Association, 1994; Hansen & 
Osborne, 1995; Renzetti & Curran, 1995). Williams, Spitzer, Linzer, Kroenke, & Hahn 
( 1995) concluded that (p. 656) "women are much more likely than men to have 
depress ive disorders ... [f]urther research is needed to determine why women seem to 
suffer disproportionately from symptoms of depression .... " Although more women are 
diagnosed with depression than men, the accepted standard for diagnosing symptoms 
among both men and women follows the criteria from the DSM-fV (Lesseig, 1996). 
Severity of Symptoms 
The severity of symptoms can be partially exp ressed by understanding the 
complications of depression. When depression is not diagnosed, the client has a greater 
chance of developing other symptoms such as medical, substance-abuse, academic, and 
work-related problems (Bhatia & Bhatia, 1997). This is significant considering " the ove r 
all national economic burden of mood disorders is approximately $44 billion" (Bhatia & 
Bhatia, 1997, p. 1683). Personal and economic problems associated with depression are 
substantial and may be magnified by the complex and time-consuming process of 
diagnosis and treatment intervention strategies. 
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Depression diagnosis must be assessed in the following areas to determine its type 
and severity and the most appropriate treatment plans: suicidal ideology, secondary 
depression, bipolar depression, psychotic depression, masked depression, seasonal 
depression, atypical depression, major depression superimposed on dysthymia, treatment-
refractory depression, and adjustment disorder with depressed mood (Bhatia & Bhatia, 
1997). A thorough evaluation of the above forms of depression is necessary to prescribe 
the optimal therapeutic (mental and/or medical) intervention. 
The process is further complicated as co-occurring conditions may compound the 
sevetity of symptoms (Lesseig, 1996). Wesi, Zarin, and Pincus ( 1997) stated that "mood 
disorders constituted the most common principal DSM-IV diagnostic category, affecting 
53 percent of the patients in this study [and] the majority [also] had significant 
psychiatric and general medica l co-occurring condi tions" (p. 79). Results from a study 
by Fava eta!. ( 1997) show that "several symptoms characteristic of eating disordered 
patients are linked to the severity of depress ive symptoms" (p. 140). Because the scope 
of depress ive symptoms and coexisting conditions is serious, proper diagnosis is 
necessary to treat the patient efficaciously. It is common practice for a medical 
practitioner to monitor patient medications in conjunction with the patient rece iving 
psychotherapy (West et a!., 1997). The combination of medication and psychotherapy is 
efficacious. Hirschfeld ( 1994) stated that "psychotherapy plays a critical function in the 
long-term treatment of depression." Patients with depression, especially long-standing or 
recurrent depression, often have serious marital , familia l, social, and occupational 
problems that have been exacerbated by their illness. In addition, psychotherapy may 
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help to improve compliance, which helps to prevent relapse" (p. 68) . 
As noted, there is a clear case for a thorough evaluation and assessment of 
depression. The severity of depress ion may render a person less capable of monitoring 
the very medication that would alleviate the problem. If a patient has a diminished ability 
to think (one of the criteria for depress ion), he or she may not be ab le to follow through 
with taking the prescribed medication. Secondly, co-occurring problems raise other 
issues rel ated to compl iance in taking medication. The first concern is misdiagnosis, 
when other symptoms are treated whi le depressive symptoms are overlooked. The 
depression may lead the person to fee l hopeless and not take the medication to help 
reduce related symptoms. The second concern with co-occurring problems is related to 
the cost of multip le medications, which may reduce comp liance. 
Antidepressant Medication Side Effects 
Medical professionals prescribe antidepressant drugs to combat depressive 
symptoms. The three major classes of drugs are the serotonin selecti ve reuptake 
inhibitors (SSRis), tricyc lic antidepressants (TCAs), and the monamine oxidase inhibitors 
(MAOis) . The SSRis are less toxic and have milder side effec ts than the TCAs 
(Montano, 1994 ). Li, Hamdy, Sandborn, Chi, and Dye r ( 1996) suggested that patients 
taking TCAs and SSRis can experience " impairment of balance function ... motor 
coord ination, fine -motor contro l, postural reflexes, maintaining equilibrium, and reaction 
time" (p. 19 1). The MAO! class of antidepressants "can cause sedation [slowing down of 
physical and mental functioning], heart palpitations [throbbing of the heart] , di zziness, 
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insomnia, sexual dysfunction [normal sexual function disturbed] , tachycardia [racing of 
the heart], constipation, agitation, and edema [swelling of tissues] ... and the possibility 
of hypertensive crisis [elevation of hypertension]" (Nemeroff, 1994, p. 5). Long ( 1998) 
observed that some antidepressant medications, particularly the tricyclics, have disturbing 
side effects, such as weight gain and weight loss. Patients using Prozac, Luvox, Paxil, 
and Zoloft (SSRl class of antidepressants) exhibit anorexia more often in overweight 
patients, and weight gain in patients after chronic use (Bezch1ibnyk-Butler & Jeffries, 
1998). Bhatia and Bhatia (1997) reported no weight gain with the use of Prozac, Luvox, 
Paxil , and Welbutrin. In the tertiary tricyclic class of antidepressants, amitriptyline 
(Elavil) exh ibits a weight gai n (over 6 kg) 30% of the time; the next highest incidence is 
with clomipramine (Anafranil), doxepin (Sinequan), and imipram ine (Tofranil), 
exhibiting weight gain 10% of the time (Bezchlibnyk-Butler & Jeffries, 1998). The 
secondary tricyclics amoxaprine (Asendin) and nortriptyline (Pamelor) show a low 
incidence of weight gain (Bhatia & Bhatia, 1997). Weight gain (over 6 kg) reported in 
the MAO! class of antidepressants is as follows: phenelzine (Nardi!), 10%, and 
tranylcypromine (Pamate), 2% (Bezchlibnyk-Butler & Jeffries, 1998). 
Often sexual functioning is affected by medications prescribed for depression 
(Crenshaw & Goldberg, 1996) through increased libido (Gartrell, 1986) or decreased 
libido (Crenshaw & Goldberg, 1996) with both being potentially problematic. The 
antidepressant medications most highl y associated wi th sexual dysfunction are the SSR.Is: 
fluoxetine (Prozac), parocetine (Paxil), sertraline (Zoloft), and fluvoxamine (Luvox); the 
TCAs: clomipramine (Anafran il), Elavi l, Endep, Norpramin, Pertofrane, Adapin, 
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Sinequan, Tofranil, Aventyl, Pamelor, Vivactil , and Surrnontil; and the MAOis: Marplan, 
Nardi! , and Pamate (Aldrich, Cook, & Pedersen, 1996; Lesseig, 1996). Welbutri n 
(bupropion), an SSRI, affects sexual dysfunction least (Aldrich et al. , 1996; Lesseig, 
1996). Antidepressant drugs also have been reported to induce other mental disorders 
such as rapid cyc ling of mood change (Oppenheim, 1982). Thus, the prob lems with 
antidepressant medication can range from mild distress to a life-threatening potential. 
"Completed suicide is a major risk in depressive illness" (Isometsa, Aro, 
Henriksson, Heikkinen, & Lonnqvist, 1994, p. 523). The connection between suicide and 
depression is a complex prob lem. If depressive symptoms cannot be diminished, then 
suicidal ideation rises (Isometsa et al., p. 78). Presc ribed antidepressants, however, have 
the risk of becoming the means fo r attempting su ic ide. When persons in major 
depress ion receive medication and become more lucid than they have been in the past, 
they may have a greater capacity for suicide ideation or even anempt the act (Slaikeu, 
1990). After starting an antidepressant drug regimen , mental hea lth professionals 
recognize the ri sk of the eminent transition from incapaci tating depress ion to increased 
functioning that may culminate in a suicide anempt or completion (Slaikeu, 1990). "It is 
recommended that the practitioner limit the prescription ofTCAs (tricyclic 
antidepressants) to a sublethal dose, particularly early in the course of therapy for 
depression, since some patients may be more energized to commit suicide as their 
depression begins to lift" (Lesseig, 1996, p. 78). 
Pati ent cooperation with medication treatment may decrease as risks and side 
effects increase. A patient may have profound discomfo rt from a side effect, namely, 
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dizziness, insomnia, sexual dysfunction, tachycardia, constipation, or edema (Nemeroff, 
1994), and discontinue the antidepressant medication. The patient may decide to 
discontinue the antidepressant medication because of the immediate discomfort it is 
causing (Long, 1998). Thus , the antidepressant medication may be discontinued before 
its beneficial effects can take place. Because of the risks and side effects associated with 
using antidepressant medication, the medical practitioner also acts as a medication 
manager, monitoring the effects of the drug and changing dosages and/or drugs as 
necessary. 
Medication Education 
Management of depress ion is a growing concern for medical doctors (Bhatia & 
Bhatia, 1997). Many family practice physicians have a strong commitment to patient 
education concerning antidepressant medication (Bhatia & Bhatia, 1997; L. Eskelson, 
personal communication, March 5, 1998; M.Gibby, personal communication, May 7, 
1998). Patient education about antidepressant medication needs to come from both the 
doctor prescribing the medication and the pharmacist. Areas of importance include the 
pharmacology, indications, contraindications, warnings, precautions, adverse effects, and 
dosage of the medication along with seasonal influences and alternatives to medication 
(Long, 1998; Luke, 1998). Knowing the fami ly history of depression and medication use 
is helpful because "response [to medication] runs in families" (Lesseig, 1996, p. 76). If 
the patient does not have a basic understanding of the chemistry and function of 
antidepressant medication, she may not realize the gravity of her recommended 
medication use and may discontinue essen tial treatment. 
Perceived Stigma 
Stigma is a rea l concern that interferes with clients reporting depression because 
they still assoc iate depression with emotional or spiritual weakness (Montano, 1994). 
Campbell ( 1996) defined stigma as a label given to people who are mentally disordered, 
whereby it justifies di scrimination against them. In a study by the National Alliance for 
the Mentally Ill (Gwirtsman, Blehar, McCullough, Kocsis, & Prien, 1997), family 
members were asked if they had experienced stigma and most families reported that 
stigma had a sign ificant effect on the family member with mental illness and family 
functi oning. Montano also reported that "nearly 70% of the respondents in a survey sa id 
that stigma was attached to admitting mental illness" ( 1994, p. 26). 
If a patient feel s he or she is stigmatized, then other emotions may follow such as 
shame, gu ilt, anxiety, fear, or anger. Max men and Ward ( 1995) described shame as an 
emotion assoc iated with embarrassment, whi le guilt is an emotion associated with 
worthl essness. To understand the responses of shame and guilt, Zukerman (1995) 
applied desc riptors to them: burdened, self-condemning, disgraced, devalued, fears 
rejection/abandonment, failure to attain goals or measure up, and wishes to disappear. 
Zukerman proposed the following dist inction between guilt and shame: shame is 
associated w ith a failure of being and guilt is assoc iated with a failure of doing. 
According to Erik Erickson's theory of development, humans must resolve the conflict of 
shame to attain se lf-con tro l, and the conflict of guilt to develop direction and purpose 
14 
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(Cole & Cole, 1993). When the depressed individual is experiencing the effects of 
stigma and associated emotions, the stress it causes may interfere with the patient's 
ability to act with the necessary degree of direction and self-control to stay in compliance 
with prescribed antidepressant medication. 
Anxiety or fear may be associated with st igma. To understand the responses of 
anxiety or fea r, Zukerman ( 1995) applied descriptors to them: adrenaline secretion, 
stomach acid production decrease, loss of bladder/ana l sphincter control, nausea, cold 
sweats/chills, faintness, chest pain, hyperventilation, difficulty breathing, and the fight-
or-flight response (a physiological stress or response to fear) which may embody the 
preceding responses and more. The Diagnostic and Statistical Manuai of Mental 
Disorders (4'" edition) defines phobias as persistent fears associated with high levels of 
anxiety (American Psychiatri c Association, 1994). According to Maslow's Hierarchy of 
Needs (Zukerman, 1995), safety is one of the basic needs that must be met to facilitate 
self-actualization (the abi li ty to meet ones physical and emotional needs). If an 
individual is not able to progress toward se lf-actualization, the associated stress may be 
over-burdening to the individual, and family/social support system. 
It appears that the emotions evoked by stigma may interfere with individual 
emotional development, which may create or exacerbate problems within the patient's 
family/social support system. When a patient already is feeling the symptoms of 
depression, the negative impact it has on the family and social support systems, the side 
effects of medication, and the difficulty assimilating the precautions associated with 
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medication use, the added anguish of coping with stigma of depression may be more than 
the patient can bear. 
Effects of Family/Social Support System 
Depression is associated with relationship problems. Research suggests that 
depressed individuals are often treated in ambivalent ways (sympathetic and hostile) and 
find great difficulty or impossibility in recovering without help (Baucom & Epstein, 
1990). Research is needed to investigate depression and relationship interaction, but 
existing research suggests that the dynamics of relationships are influenced by depression 
(Coyne, i 987). Some of the problems associated with depression include the fact that 
individuals often fail to find pleasure in life, suffer from energy loss, cry often, have 
numerous physical complaints, cannot function optimally, and have suicida l ideation 
(Coyne, 1987; Lambert & Burlingame, 1996; Lesseig, 1996). 
Because of these problems associated with depression, the family/social support 
system is affected negatively. Coyne ( 1987) stated that the entire family of a depressed 
person is at considerable risk for negative outcomes. Coyne also stated that the 
relationships between depressed persons and their spouses are often conflictual and 
overtly hostile. Baucom and Epstein ( 1990) stated that a circular pattern tends to develop 
in families of depressed individuals "in which negativity and lack of positive 
responsiveness on the depressed spouse's part elicits hostility and withdrawal from the 
partner, which in tum elicits anxiety, more depression and demand for reassurance by the 
depressed person" (p. 114). Baucom and Epstein ( 1990) further stated that because of the 
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circular negative communication pattern, couples may require extensive intervention, but 
the depressed individual may be so depressed that he or she is unable or unwilling to 
participate in therapy. Fava eta!. ( 1997) reported that the severity of depression may 
heighten interoceptive awareness or interpersonal distrust, resulting in a sense of 
alienation and reluctance to form close relationships. From the reports of Coyne ( 1987), 
Baucom and Epstein ( 1990), and Fava et a!. ( 1990), it appears that depress ion adversely 
affects the famil y/social support system. 
Research shows that the following factors are associated with depress ion: 
biogenetic, family history, family environment, social background, temperament, mood, 
interpersonal/cognitive abilities , socia l context, stressors, personal resources, and soc ial 
resources (Kupfer & Frank, 1998). Kupfer and Frank discussed recent efforts to develop 
assessment of psychosocial and biologica l risk factors associated with depression that 
may develop a more integrated theory to further explain the impact of depress ion. 
Another facto r associated with depression that impacts the fami ly/social support 
system is the fact that medical conditions , chronic illnesses, and other disorders often co-
occur with depression (Lesseig, 1996; Fava et al., 1997). Chronic illness such as multiple 
sc lerosis, certain viruses and cancers, and thyroid and/o r adrenal disorders co-occur with 
depress ion (Lesseig, 1996). There is also evidence linking eating disorders to depression 
(Fava eta!., 1997). It is clear that for a patient and fam ily dealing with depression and 
co-occurring problems, a significant burden exists. 
Once treatment (antidepressant medication) begins, the patient and family find 
that it takes approximately 4 to 6 weeks fo r the medication to take effect and relieve some 
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of the depressive symptoms (Lesseig, 1996). If the medication has to be changed fro m an 
SSRl to a MAO! there are washout periods, defined as the time needed between stopping 
one drug and beginning the other (Lesseig, 1996). The washout period for switching 
from an SSRJ to a MAO! is 2-5 weeks. Thus, the family and patient find that though 
treatment has begun, they may still be burdened by the effects of depression for another 
2-3 months before some symptom alleviation occurs. 
Another disrurbing siruation arises for the family when the late-emerging adverse · 
effects of SSRls occur. The late-emerging adverse effects, namely, anorexia, anxiety, 
fatigue, insomnia, and/or sexual dysfunction , can be confusing because the patient and 
family may think the depression is worsening instead of getting better (Lesseig, 1996). 
Summary 
The symptoms of depression place a considerable strain on the depressed person 
and her relationsh ips. Without support from fami ly, friends, and cohorts, the added 
burden of seeking and following through with treatment may be overwhelming. The 
severity of the depression alone may be so great that it interferes with her ability to 
comply with medication prescription. When the pattern of connection among the 
correlates that con tribute to disuse of antidepressant medication is discovered, specific 
interventions can be used to support the patient in managing her depression. 
The specific null hypotheses for this srudy involve the five contexrual issues 
correlated with medication compliance or noncompliance: 
I. Severity of symptoms: Patients who report severe symptoms of depression are 
no more likely to discontinue medication treatment than patients who report mild or 
moderate symptoms. 
2. Medical side effects: Patients who report adverse medication side effects are 
no more likely to spontaneously discontinue medication treatment than patients who do 
not experience medication side effects. 
3. Medication education: Patients who can express the properties of the 
antidepressant medication and their possible side effects are no more likely to continue 
medication as prescribed than patients who cannot express the properties and effects of 
an antidepressant medication. 
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4. Perceived stigma: Patients who report a low leve l of stigma are no more likely 
to continue antidepressant medications than patients who report a high degree of stigma. 
5. Effects on family/soc ial support system: Patients who strongly agree that 
depression has had a negative effect on their family/social support systems are no more 
likely to discontinue antidepressant medication use than patients who disagree that 
depression has had a negative effect on their family/socia l support systems. 
CHAPTER ill 
METHODS 
Design 
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This is a correlational study of the degree of association between the variab les 
being sntd ied. Correlational stud ies examine relationships between variables without 
experimenta l manipulation (Miller, 1986). The variables in this study (severity of 
symptoms, medical side effects, medication education, perceived stigma, and effects on 
family/soc ial support system) were not controlled or manipulated but examined ex post 
fac to (after they occurred). A medical usage questionnaire (see Appendix B) was used to 
gather data about the variab les. To strengthen the design, a double-b lind study was used, 
meaning that the women who answered the questionnaire and the persons who 
admini stered the questionnaire were not informed about the research quest ions (null 
hypotheses). 
Sample 
Data were collected from September 1999 to March 2000. It was estimated that 
each provider would see 30 to 40 female patients with depression during the time of the 
study. Women were chosen as the population for this study rather than men and/or 
ch ildren because the correlates may vary according to gender and age. In addition, 
studies indicate that depressive episodes occur twice as frequently in women as in men 
(American Psychiatric Association, 1994). 
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The sample of women surveyed consisted of 35 women who had been previously 
prescribed antidepressive medication and who came back into the doctor's office for any 
reason. The women surveyed were 18 years of age up to age 72, with an average age of 
39. On average, respondents had three children, had attended about a year of college, 
and had a household income of $46,000 (see Table I). 
Table I 
Demographic Summarv of the Sample 
Catego~ n Minimum Maximum Mean so 
Age 34 18.00 72.00 39.26 L 1.87 
Number of children 34 .00 7.00 3.00 1.92 
Total household income (in 1000s) 28 12.00 120.00 46.62 27.94 
Years of education comeleted 34 12.00 19.00 12.82 3.57 
Almost three fourths of the sample were not receiving therapy, but of those that 
were, most reported benefitting (see Table 2). Six women noted they would be interested 
in receiving information about psychotherapy. The population for this study included the 
female patients of one psychiatrist (!2 = 7); four family practice physicians (!2 = 12); and 
two certified physician assistants (!2 = 16) from the Cache Valley region, located in both 
northern Utah and southern Idaho. 
Measurement 
The survey included an introductory statement explaining that many women have 
found it difficult to stay on their medications. A medical usage questionnaire was 
devised to gather demographic infonnation; symptoms, social support, side effects, and 
medication compliance. 
Table 2 
Sample Resources or Needs Related to the Treatment of Depression 
Yes No 
Resources/Needs n % (n) % (n) 
Receiving therapy 33 27.30 (9) 72.70 (24) 
Therapy/medication are helping 14 85.70 (12) 14.30 (2) 
Need infonnation about therapy 28 21.40 (6) 78.60 (22) 
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The Outcome Questionnaire (OQ'm-45.2; Lambert & Burlingame, 1996) is a 45-
item, self-report questionnaire. The assessment is measured on a summated rating scale 
or Likert-type scale, in which the responses to the questions are answered along a 
continuum with five possible choices ranging from "never" to "almost always." The 
questionnaire assessed three areas: symptom distress, interpersonal relationsh ips, and 
social role. The resulting sco res can be more infonnative if the clinical cutoffs are used 
rather than using the raw scores. Scores above the cli nica l cutoffs are indicati ve of 
diagnosable problems. The symptom distress subscale consists of 25 questions assessing 
symptoms of depression, anxiety, and substance abuse. Total scores range from 0- l 00, 
with 36 being the clinical cutoff. The interpersonal relationship subscale uses 11 
questions to detennine distress in marriage and family relations. Scores range from 0-44, 
23 
with 15 being the clinical cutoff. Social role distress is a nine-item subscale to determine 
problems related to work, friends, and society. Scores range from 0-36, with 12 being the 
clinical cutoff. Each questionnaire area was scored separately and then the three scores 
were added together for a total score. The cutoff score for the whole measure is 63, with 
scores above this representing clinically significant symptoms. 
The OQ <m_ 45.2 is a standardized measure with established reliability and 
validity. Both the internal consistency and test-retest va lues have high coefficients. The 
va lues are reported in each area with the internal cons istency value preceding the test-
retest reliability value: symptom distress (.92; .78), interpersonal relationships (.74; .80), 
social ro le (.70; .82), and an OQ <m_ 45.2 total score (.93; .84; Lambert & Burlingame, 
1996). 
Concurrent validity was estimated by using the Pearson product-moment 
con·elation coefficients (Cohen, 1988) on the total OQ <m_ 45 score and on individual 
domain scores that correspond to segments in ll other tests accepted in the field as being 
valid. The criterion measures were all significant beyond the .01 level of confidence 
(Lambert & Burlingame, 1996). The counterparts to the OQ <m_ 45.2 and their values (the 
first value is the correlation with the symptom distress component and the second value is 
for the total OQ <m_ 45.2 value) include the General Symptom Index of the Symptom 
Check List- 90-Revised (SCL-90-R) (.61; . 78); Beck Depression Inventory (BDI) (.63; 
.80]; Taylor Manifest Anxiety Scale (TMA) (.88; .86]; State-Trait Anxiety Inventory 
(STAI Y-2) (.65; .80]; Inventory of Interpersonal Problems (liP) (.62; .54]; Social 
Adjustment Scale (SAS) (.45; .65]; SF-36 Medical Outcome Questionnaire (SF-36) (.80; 
.81]; and the Friedman Well -Being Scale (FW-B) [.77; .81] (Lambert & Burli ngame, 
1996). 
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The conclusion is that the OQ 'm- 45.2 is va lid because the concurrent validity 
va lues are significant beyond the .0 l leve l when compared with I 1 other tests accepted as 
valid in the fie ld. The internal consistency and test-retest reliability values in each area 
are also high, ranging from . 70 to .93 (Lambert & Burlingame, 1 996). The calcu lated 
total reliability score for the OQ ,m_ 45.2 is .84 (Lambert & Burlingame). The Cronbach's 
alpha fo r the present sample was .95 for symptom distress, .89 for interpersonal 
re lationship, .93 for social ro le, and .94 for the overall measure. 
The medical usage questionnaire, consisting of 25 questions, assessed 
demographic information, the dependent and independent variab les, and involvement 
with psychotherapy. Demographic information assessed included age, number of 
ch ildren, income, education, religios ity, and marital status. Age, number of children, 
income, and education were determined by write-in questions to determine a specific 
answer rather than a general category. The write-in questions were des igned to increase 
vari ability for measurement. Marital status was determined using questions formatted 
like those used by the United States Census Bureau for the 2000 census: married , 
divorced, separated, and never been married (U. S. Census Bureau, 1 998) 
Religiosity was measured to determine the assoc iation between religios ity and an 
objection to taking medication for a psychological condition. Religiosity was measured 
using questions from the Intri nsic Religious Motivation Scale (IRMS; Hoge, 1972). 
Hoge deve loped the IRMS as a measure of motivation for religious behavior. The !RMS 
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contains I 0 items with a Likert-type scale. Intrinsic religiosity is a strong religious 
motivation and extrinsic religiosity is the relative absence of religious motivation (Hoge). 
A reliability coefficient of .90 was achieved by Hoge utilizing the Kuder-Richardson 
formula 20, and the IRMS also corre lated .8 5 with Feagin's Intrinsic-Extrinsic Scale 
(Hoge). The Soderson adaptation of the IRMS was used because of the increased scoring 
choices for the purpose of increasing variab ili ty among the scores: strongly agree, 
moderately agree, slightly agree, slightly disagree, moderately disagree, and strongly 
disagree (Hoge). Each item was assigned a point value and high scores indicated more 
intrinsic religious motivation and low scores indicated less intrinsic religious motivation 
(1-Ioge). The fRMS assumes that extrinsic religious motivation ts the relative absence of 
intrinsic religious motivation (1-Ioge). Four questions from the IRMS were deemed 
appropriate for the survey. The Cronbach 's alpha for the four questions used in the 
present sample was .83, which justifies the appropriateness of the chosen questions. 
The next segment of the medical usage questionnaire asked, " Have you 
disco ntinued your antidepressant medication on your own?" The yes/no response format 
was designed to determine if the patient was being compliant or noncompliant in the use 
of the prescribed medications. 
Antidepressant medication side effects were assessed using four Likert-type 
questions wi th fi ve possible responses. The questions asked about four common side 
effects associated with sexual functioning and weight variation. The questions were 
chosen from in formation in the current li terarure concerning antidepressant medication 
(Aldri ch et al., 1996; Bezchlibnyk-Butler & Jeffries, 1998; Crenshaw & Goldberg, 1996; 
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Gartrell , 1986; Lesseig, 1996; Nemeroff, 1994; Oppenheim, 1982). [n addition, the five 
medical professionals who participated reported the questions had both face and content 
validity. lntemal reliability for these questions had an alpha coefficient of .69. 
Medication education was assessed with three Likert-type questions with five 
possible responses. The questions inquired how informed the patient was about the 
chemical properties and usage of her medication. The questions were formed from 
personal communication and by reading the current literature about medical education 
concerning antidepressant medication (Bhatia & Bhatia, 1997; L. Eskelson, personal 
communication, March, 1998; M. Gibby, personal communication, May, 1998; Lesseig, 
1996; Long, 1998; Luke, 1998). The five medical professionais also reported these 
questions had face and content validity. The statistical reliability of these quest ions for 
the current sample was a Cronbach's alpha of .82. 
To assess the presence of stigma, two six point Likert type questions were asked. 
The questions were taken from the current literature on stigma and depression 
(Gwirtsman et al., 1997; Montano, 1994). Patients were asked if they felt there was a 
stigma attached to depression and if someone in their family feels there is a stigma 
attached to depression. These questions were also reported to have face and content 
validity by the medical profess ional s. The internal reliability for these questions was .7 1. 
The final two questions were "yes" or "no" questions to assess the presence and 
desire for psychotherapy in connection with the patient's depression. Coyne (1987) and 
Hirschfeld (1994) acknowledge the beneficial effect of psychotherapy in connection with 
depression. Reference materials were left in the offices of the participating medical 
practitioners for the patient who wanted more information from a therapist concerning 
her depression. 
Procedures 
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Data collection began by contacting health care practitioners who had prescribed 
antidepressive medication to female patients diagnosed with depression. Each 
practitioner delineated the methods used to assess depression. The participating 
practitioners were interviewed concerning the problem of their female patients 
spontaneously discontinuing their med ications. The medical professionals were asked to 
describe the treatment cycle for depression and their evaluation of that process. It was 
deteim ined that some women start medication, spontaneously discontinue medication, 
and then return to the physician's office and begin treatment again (L. Eskelson, personal 
communication, March 5, 1998; M. Gibby, personal communication, May, 1998). 
A packet containing a brief explanatory paragraph to the patient, the OQ <m - 45.2, 
and a medication usage questionnaire was delivered to the practitioners for their 
approval. It was delivered with a cover letter exp laining the research statement: "We are 
conducting a study to find more about how women use antidepressant medication 
prescribed by their physic ian and what influences these decisions." Office personnel who 
distributed and received the surveys were oriented by the practitioner and trained by the 
researcher. The packet was then distributed, by the nurse, to patients who the practitioner 
determined would participate. This was conducted in the doctor's treatment room to 
promote professionalism and create a convenient private place to answer the questions. 
28 
A consent waiver and confidentiality fonn and two questionnaires were used to 
collect data. The questionnaires were the OQ •m_ 45.2, and a medication usage 
questiollnaire. As patients presented at the physician's office for treatment, a packet 
containing the fonns was given to clients who had previously been prescribed 
antidep ressant medication. This was the standard method of administering the 
questionnaires. Questions involving the independent variables indicated patient concern 
in each of the several areas. 
The questionnaire was designed to be completed in fifteen minutes. The survey 
served a two-fold purpose: (I) to provide data for this research and (2) and to provide an 
indication of patient thought process. The answers were computer coded for statistical 
analysis. The results were shared with the physicians for use with their patients. 
Ethical Considerations 
An Institutional Review Board (IRB) review was conducted prior to surveys 
being distributed. All universities that conduct research with human subjects are 
mandated by federal guidelines to have an IRB (Leary, 1995). The purpose of the IRB 
review is to assure protection of human subjects associated with research projects 
(Leary). A written proposal of the research was subm itted to and approved by the IRB 
(see Appendix A). 
The survey given to the women initially began with an infonned consent in the 
introductory paragraph explaining the research. The infonned consent included risks, 
benefits, confidentiality, and patient rights (see Appendix B). The surveys were 
anonymous to secure confidentiality of answers and the participants cou ld decline 
to take the survey. 
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CHAPTER IV 
RESULTS 
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In this chapter the degree of association is reported between the independent 
variables and compliance with an ti depressant medication as stated in each null 
hypothesis. The dependent variable (DV) is compliance/noncompliance with medication 
prescription as stated. There were 19 patients who were in compliance with medication 
and 15 were not. There is some variance in the number of noncompliant/compliant 
patients because of missing data for the independent variables. The independent 
variables (IV) are interval level measu res: severity of symptoms, medical siue effects, 
medication education, perceived stigma, and effects on family/social support system. 
The appropriate analyses for this study was the l test. A l test was chosen to 
determine whether mean scores differed for those who discontinued medication, 
compared with those who remained in compliance. The assumptions for the single-
sample 1 test are (a) there was one random sample of interval sco res ; (b) the raw sco re 
population formed a normal distribution for which the means is the appropriate measure 
of central tendency; and (c) the standard deviation of the population (patients in 
medication compl iance and those in noncompliance) was estimated to be the same 
(Heiman, 1996). The dependent variab le (DV) was a dichotomous measure 
(comp liance/noncompliance of medication) and the independent variable (IV) is an 
interval level measure. The 1 test compares means and from those means, test statis tics 
demonstrate the abil ity of the data to meet the criteria to show stati stical sign ificance. 
ln addition to the l test, it was appropriate to go one step further to report the 
effect size. Effect size is a measure of the strength of a relation. Vogt ( 1993, p. 79) 
stated that 
tests of the null hypothesis only allow you to conclude that a relation is 
sign ificantly larger than zero, but they do not tell you by how much. 
Effect size measures do. Thus the effect size is an estimate of the degree 
to wh ich a phenomenon is present in a population and/or the extent to 
which the null hypothesis is false. 
31 
Effect size was calculated by subtracting the mean of patients who discontinued 
medication usage from the mean of patients who continued with medication usage. The 
difference wo.s then divided by the standard deviation of those who continued medication 
usage (Durlak, 1995). The scores were then recorded in absolute values. The 
transformation into effect sizes reflects the relati ve magnitude of effect in a common 
term, standard deviations, allowing for meaningful comparisons from one variable to the 
next. In this study, an effect s ize of l.O would mean that the medication compliance 
score differed one standard deviation higher or lower than the medication noncompliance 
score. Durlak reported that "effect sizes of around 0.20 have a small magnitude of effect, 
those around 0.50 have a medium magnitude of effect, and those around 0.80 have a high 
magnitude of effect" (p. 328). However, in some areas of research, mean effects of 0.50 
may be considered large (Vogt, 1993). 
To test hypothesis 1 (severity of symptoms: patients who report severe symptoms 
of depression are no more like ly to discontinue medication treatment than patients who 
report mild or moderate symptoms) the symptom distress subscale of the OQ •m-45.2 was 
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used as an indicator of symptom severity. Medication compliance/noncompliance was 
the dependent variable . The! test for this hypothesis did not reach levels for statistical 
significance (see Table 3). 
Patients who di scontinued medication reported more severe symptoms than those 
who continued medication. It should be noted that the mean scores in the present sample 
are above the clinical cutoff parameters representing symptom distress for both groups. 
The effect s ize in the present srudy was .58, which represents a medium to large 
assoc iation. 
Table 3 
Patients in Noncompliance/Compliance with Antidepressant Medication Paired with 
Severitv of Symptoms 
Patients n = 30 
Noncompliant patients 
(Medication 
discontinuance) 
M SD 
Compliant patients 
(Medication 
continuance) 
M SD g ES 
Severity of symptoms 46.77 17.8 1 39.32 12.80 1.38 . 19 .58 
While the two groups (those in medication compliance, and those in 
noncompliance) were not statistically different, the effect sizes do indicate a strong 
association in the expected direction. The trend is that patients who were noncompliant 
with their antidepressant medication prescription had a greater degree of symptom 
distress. While the trend is noticeable, the differences were not statisticall y different, and 
hence the null hypothesis must be accepted. 
One possibility for the distress scores being so high is that the underlying 
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problems are not being treated by the antidepressant medication. To assess this, a 
frequencies table was done to compare medication noncompliance/compliance and 
receiving some type of psychotherapy (see Table 4). Then was too low for statistical 
analysis. The low numbers of women receiving therapy were evenly spread between the 
medication noncompliant and compliant groups. 
Table 4 
Frequencies Comparing Medication Noncompliance/Compliance with Receiving Therapy 
Noncompliance Compliance 
(medication (medication 
Groups discontinuance) continuance) 
Receiving therapy 5 4 
No therapy 13 10 
Total 18 14 
To test hypothesis 2 (medical side effects: patients who report medication side 
effects are no more likely to spontaneously di scontinue medication treatment than 
patients who do not experience the most common medication side effects) four questions 
concerning side effects were used. The first two questions read, " ! have experienced a 
10% weight gain since taking my antidepressant," and"! have experienced a 10% weight 
loss since taking my antidepressant medication," and were answered yes or no. With a 
dichotomous independent variab le, the most appropriate analysis for both weight loss and 
gain was chi square. The frequencies and analyses are found in Tables 5 and 6. Ph i, a 
measure of association, was also calculated. 
Table 5 
Frequencies and Chi-Square Analysis Comoaring Medication Noncompliance/ 
Compliance with Weight Gain 
Category 
Weight gain Yes 
No 
Note . Chi square= 1.11 
Table 6 
Noncompliant patients 
(medication 
discontinuance) 
n (%) 
8 (47%) 
4 (29%) 
Q = .29 phi = .19 
Compliant patients 
(medication 
continuance) 
n (%) 
9 (53%) 
10 (71%) 
Frequencies and Chi-Square Analysis Comparing Medication Noncompliance/ 
Compliance with Weight Loss 
Category 
Weight loss Yes 
No 
Note . Chi square= 1.56 Q= .21 
Noncompliant patients 
(medication 
discontinuance) 
n (%) 
3 (60%) 
7 (30%) 
phi= .24 
Compliant patients 
(medication 
continuance) 
n (%) 
2 (40%) 
16 (70%) 
The other questions, "I have problems with my own low sexual interest or desire 
that seems to be related to antidepressant medication" and "I have problems with sexual 
functioning that seems to be related to antidepressant medication," were posed as Likert 
questions and were tested with! tests. The results for both questions are found in 
Table 7. The DV was medication compliance/noncompliance (see Table 7). 
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Table 7 
Patients in Noncompliance/Compliance with Antidepressant Medication Paired with 
Medication Side Effects 
Noncompliant patients Compliant patients 
(medication (medication 
discontinuance) continuance) 
Patients M so M so Q ES 
Loss of sexual 
interes t (!L = 34) 3.00 2.04 3.53 2.04 .72 .48 .11 
Loss of sexual 
function (n = 34) 3.23 2.24 3.47 2.06 .70 .75 .11 
An examination of the data shows that reducing the data to mean scores loses 
valuable information. There appears to be a clear curvilinear re lationship with the 
majority of the women being fairly equally represented at both ends of the responses. A 
frequency table shows the raw scores for the women in the sample (see Table 8). 
The null hypothesis stated that patients who reported medication side effects 
would be no more likely to spontaneously discontinue medication treatment than patients 
Table 8 
Freguencv Rate of Patient ResQonse to Sexual Side Effects 
Likert choices 
2 3 4 5 6 
Category Strongly agree Strongly disagree 
Loss of sexual interest 10 4 3 3 5 9 
Loss of sexual function 9 6 3 5 10 
who were not informed about medication side effects. Since none of the analyses were 
statistically significant, the null hypothesis must be accepted 
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To test hypothesis 3 (medication education: patients who can express the 
properties of the antidepressant medication and their possible side effects are no more 
likely to continue medication as prescribed than patients who cannot express the 
properties and effects of an antidepressant medication), three questions concerning the IV 
(medication education) were used: "When you were prescribed antidepressant 
medication, how well did your physician explain the properties of the medication and 
what you could expect?"; " When you filled your prescription for antidepressant 
medication, how well did your pharmacist exp lain the medication and what you could 
expect?"; and "Did your physician or pharmacist inform you abo ut the side effects of 
you r medication?" A low score meant the patient received more information. The DV 
was medication compliance/noncompliance (see Table 9). 
An examination of the mean scores shows that the women believed their 
physicians explained the properties of the medications. The women also thought the ir 
pharmacists exp lained the medications but not as well as their physicians. The 
explanation on the possible side effects was made clear for the women by both the 
physicians and pharmacists. 
The null hypothesis stated that patients who could identi fy the properties of the 
antidepressant medication and their possible side effects would not be more likely to 
continue medication as prescribed than patients who could not express the properties and 
effects of an antidepressant med ication. None of the statistical analyses were statistically 
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Table 9 
Patients in Noncompliance/Compl iance with Antidepressant Medication Paired with 
Medication Education 
Noncompliant patients Compliant patients 
(medication (medicatio n 
discontinuance) continuance) 
Questions M so M so 1 Q ES 
Explanation of 
properties by 
physician (n_ = 30) 1.75 .75 1.94 .80 -.67 .51 .24 
Exp lanation of 
properties by 
pharmacist (!! = 29) 2.58 1.3 1 2.64 1. 00 -.15 .88 -.05 
Explanation of 
side effects (n = 3 1) 2.31 l.l l 2.22 l.l 7 .21 .84 .07 
s ignificant. Since the results were not statistically sign ificant, the null hypothes is was 
accepted. 
To test hypothesis 4 (perceived stigma: patients who repo rt a low degree of 
stigma are no more likely to di scontinue antidepressant medications than patients who 
report a high degree of stigma), medication compliance/noncompliance was used as the 
dependent variable: "Have you discontinued your antidepressant medication? The IV 
was measured three ways. The first component of stigma was a fa ith measure used to 
indicate the patient's perception of faith, and indi rectly her perception of stigma 
concerning her relationship with deity. The second component of the stigma measure 
was patient report that she feels stigma is attached to depression. The final stigma 
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measure was the patient' s report that the family feels there is stigma attached to 
depression. 
The patients who discontinued medication reported virtua ll y the same level of 
faith as those who continued medication. Both groups reported high degrees of faith, 
scoring over three fourths of the available responses. Thus in the first component, the 
women did not report feeling stigmatized by their faith, which is consistent with the null 
hypothesis (see Table 1 0). The second and third components of stigma (self-perception 
of stigma and perception of stigma by others) were also tested and were not statistically 
different (see Table 10). 
The means in all three analyses were not statistica lly different. An examination of 
the raw data revealed some interesting trends for stigma from se lf and others. Over one 
Table 10 
.Patients in Noncompliance/Compliance with Antidepressant Medication Paired wi th 
Perceived Stigma 
Stigma 
Religion stigma 
C!:! = 33) 
Stigma of self 
(!!._ = 32) 
Stigma from others 
(n = 33) 
Noncompliant patients 
(medication 
discontinuance) 
M SD 
19.38 4.77 
3.46 2.18 
2.38 1.56 
Compliant patients 
(medication 
continuance) 
M SD ES 
19.79 5.25 -.22 .82 .07 
3.18 1.74 4.00 .69 .13 
3.17 1.86 -1.24 .23 .42 
Table II 
Patient 's Antidepressant Medication Usage and the Association with Self-Perception of 
Categories 
Strongly agree 
Moderately agree 
Slightly agree 
Sl ightl y disagree 
Moderately disagree 
Strongly disagree 
Noncompliant patients 
(medication 
discontinuance) 
5 
2 
2 
0 
Compliant patients 
(medication 
continuance) 
3 
7 
3 
3 
half of all the women reported feeling moderately or strongly stigmatized. For those 
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who were medication compliant, one third reported not feeling stigmatized (see Tablell ). 
There was a clear bimodal trend in the women's report of fee ling stigmati zed by 
others. One half of the women reported feeling strongly or moderately stigmatized by 
others. Over a third reported strong or moderate disagreement that they fe lt stigmatized 
by others (see Table 12). 
In relation to the null hypothesis (patients who report a low degree of stigma are 
no more likely to discontinue medication treatment than patients who report a high 
degree of stigma) there were not statistically significant differences. The trend was 
inconsistent with the nul l hypothesis, but because the values did not reach statistical 
significance, the null hypothesis must be retained. 
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Table 12 
Patient's Antidepressant Medication Usage and the Association with 
Other ' s Perception of Stigma 
Noncompliant patients Compliant patients 
(medication (medication 
Categories discontinuance) continuance) 
Strongly agree 3 3 
Moderately agree 4 5 
Slightly agree 0 2 
Slightly disagree 0 2 
Moderate) y disagree 2 3 
Strongly disagree 4 2 
To test hypothesis 5 (effects on family/soc ial support system: Patients who 
strongly agreed that depress ion had a negative effect on their fam il y/social support 
systems are no more likely to discontinue antidepressant medication use than patients 
who disagree that depression has had a negative effect on their family/social support 
systems). This analysis was done with l tests. There were no statistically significant 
differences between the medication compliant and noncompliant groups in their family or 
social support scores (see Table 13). 
Patients who discontinued their medication had scores over the cutoff level in 
both the area of interpersonal relationship and social role. Those who continued their 
medication had scores below the cutoff level in interpersonal relationship and social role. 
The effect size for interpersonal relationship (.57) is considered a medium magnitude of 
Table 13 
Patients in Noncompliance/Compliance with Antidepressant Medication Paired with 
Effects on Family/Social Support System 
Category (n = 32) 
Interpersonal relationship 
Social role 
Noncompliant 
patients 
(medication 
discontinuance) 
M SO 
17.23 7.25 
12.15 7.23 
Compliant 
patients 
(medication 
continuance} 
M so t 
13.58 6.37 \51 
1121 3.71 .49 
effect, which indicates that there is a relationship between the IV and the OV. 
p ES 
.14 .57 
.67 .26 
4 1 
The effect size for soc ial rol e (.26) is considered a small magnitude of effect, but 
still indicates a relationship between the IV and OV. Since the groups were not 
statistica lly different, the null hypothesis must be retained. 
CHAPTER V 
DISCUSSION 
This chapter consists of several parts. First, the null hypotheses are discussed in 
the order previously presented. The discussion centers on what the results mean as well 
as tying each hypothesis to the existing literature. In addition, the d iscussion addresses 
the implications this study has for the practice of marriage and family therapy. 
Limitations of the study are considered, and recommendations are made for future 
research. 
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The first hypothesis, addressing severity of symptoms, was posed as a null 
hypothesis: patients who report severe symptoms of depression are no more likely to 
discontinue medication treatment than patients who report mild or moderate symptoms. 
The null hypothesis was accepted because the stati stical testing did not reach a level of 
significance. However, the trend is in the direction found in the literature. An 
examination of the mean scores for both groups shows that patients reported high levels 
of symptoms, whether they were medication compliant or not. Because both groups 
reported sym ptom distress levels above the cutoff level for the OQ '"' - 45.2, this finding is 
only partially consistent with the literature . The expected trend for patients in compliance 
with medication would be a subclinical level of symptom distress. 
The severity of symptoms can be partially expressed by understanding the 
complications of depression. When depression is underrated, the client has a greater 
chance of developing other problems, namely, medical, sustance-abuse, academic, and 
work related, all of which may reduce medication compliance (Bhatia & Bhatia, 1997). 
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West eta!. (1997) stated that a majority of the patients "had significant psychiatric and 
general medical co-occurring conditions; 20 percent of the patients had at least three 
DSM-fV Axis I mental disorders" (p. 79). Thus it may be that if the symptoms of 
depress ion are great and other problems develop, the chance for medication compli ance 
is low. However, according to the OQ <m_ 45.2, the women in this study were still in the 
clinicall y sign ificant range of di stress, even though many were in medication compli ance. 
There are at least three possible explanations for distress and medication comp li ance. 
The firs t is that individual medications may not be at a therapeutic dosage and therefore 
not effecti ve. It may also be possible that the prescribed medications do not work fo r 
some women. Some patients require psychotherapy in conjunction with medication to 
stay in medication compliance (Hi rschfeld, 1994). West eta!. (1997) noted that it is a 
common practice to couple antidepressant medication treatment with psychotherapy. 
Further, Hirschfe ld stated that it is not only efficacious but critical to include 
psychotherapy in the treatment of depression. With this recommendation availab le in the 
literature, it was surprising that just over a quarter of the women were receiving any type 
of therapy. It is not known how many women tried therapy or how successful they felt 
their treatment was. This trend speaks to the need for the doctors and therapists to work 
together dea ling with depressed cli ents. 
The second null hypothesis concerning medical side effects was stated thus: 
patients who report medication side effects are no more likely to spontaneously 
discontinue medication treatment than patients who do not experience medication side 
effects. The side effects included in the survey (sexual functioning , sexual interest, 
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weight loss, and weight gain) did not show a statistically significant relationsh ip between 
them and medication compliance. An exam ination of the data shows that 55% of the 
women experienced a 10% weight gain. In addition a small number reported a 10% 
weight loss . There was a slight trend in the side effects related to sex. Women who were 
not compliant in taking their medications reported more of a concern that their sexua l 
functioning was negative ly affected by the medications. None of these trends were 
statistically signi fi cant. However, Dr. Eskelson (personal communication, March 5, 
1998) bas reported that few women report side effects (because of an assumption that 
side effects must be endured) when asked how they are responding to the medication. 
Embarrassment concerning sexual side effects may also be a deterrent to reporting 
effects . The frequencies of the women 's responses for sexual side effects were 
interesting. The majority of the women strongly agreed or disagreed that the medications 
affected their sexual desire or functioning. This response set is somewhat unusual for a 
Likert-type question, indicating the women had clear opinions or experiences. Almost 
half of the women strongly or moderately agreed that the medications caused sexual 
problems, which is consistent with the literature. It may be that the other half of the 
women, who strongly or moderately disagreed, were on medications that did not cause 
those same sexua l side effects. 
The patient may decide to discontinue the antidepressant medication because of 
the immediate discomfort it is caus ing (Long, 1998). Thus, the antidepressant medication 
may be discontinued before its beneficial effects can take place. It may be that the degree 
of distress caused by the medication in conjuncti on with the degree of distress the patient 
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has from the depression put some patients at more risk for medication noncompliance. If 
patients have profound discomfort from side effects, they often discontinue the 
antidepressant medication (Nemeroff, 1994). The trend of this study is generally 
consistent with the existing literature; patients who reported a greater degree of distress 
also tended to discontinue their antidepressant medication. 
The third null hypothesis focused on medication education: patients who were 
informed about the properties of the antidepressant medication and their possible side 
effects are no more likely to continue medication as prescribed than patients who were 
not informed. The analyses showed no differences in compliance when compared with 
explanation of the medication properties or side effects. The means reveal that the 
women felt their doctors gave very detailed information about the medications. The 
explanation of drug properties by the pharmacists was rated as detailed. The explanation 
of the possib le side effects from both the doctors and pharmacists was also described as 
detailed. This is consistent with the doctors ' report. All of the health practitioners in this 
study reported that they include information on how the medications work as well as 
possib le side effects in their patient education (D. Beckstead, personal communication, 
April, 1998; L. Eskelson, personal commun ication, March, 1998; M. Gibby, personal 
communication, May, 1998; P. Jones, personal communication, November, 1998; J . 
Kirby, personal communication, December, 1998; K . Wade, personal communicati on, 
November, 1998; R. Wortham, personal communication, November, l998). Whi le the 
doctors all reported providing patient information, an examination of the raw data 
showed that two women reported their doctors gave no explanation. Eight women 
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reported their pharmacists did not explain the medication properties. Six women reported 
neither their doctor nor pharmacist explained the side effects. It is poss ible that the stress 
of depression interfered with patient ability to assimilate the physician/patient education 
process. It is also possible that the medical professionals assumed the patients knew 
more than they actually did. 
Another component of patient education is that it is helpful to know the family 
history of the patient because type of patient response runs in families (Lesseig, 1996). 
Thus it is important to know if the patient has a family history of experiencing side 
effects or habitual medication compliance or noncompliance. Dr. Gibby (personal 
communication, May, 1998) and Dr. Eskelson (personal communication, March, 1998) 
also reported that the response of the family to antidepressant medication can have a 
greater effect on the patient staying in compliance than the education given by the doctor. 
This is understandable when viewed through the lens of general systems theory. 
Feedback loops are a major factor in GST (Guttman, 1991). If the family 's response is 
more important to the patient than the practitioner's response, that results in a positive 
feedback loop, or a reinforcing of the originai belief. If the practitioner's information is 
more valuable to the patient than the family's perception, a negative feedback loop 
occurs. The negative feedback loop is a deviation from the original belief, or it 
represents change. In summary, the majority of the women felt informed about the 
properties and side effects of the medication. It is notable, however, that a sizab le 
number of women reported having little or no information. 
The fourth null hypothesis focused on perceived stigma: patients who report a 
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low degree of stigma are no more likely to continue antidepressant medications than 
patients who report a high degree of stigma. Three areas of stigma were assessed. For 
the first area, questions concerning faith were asked to determine if patients feel that God 
does not approve of them. This was an measure of intrins ic religious motivation, not 
extrinsic motivation. Thus the deeply held persor.al convictions about relationship with 
deity were addressed. The results showed the compliant and noncompliant group means 
were very similar and statisticall y nonsignificant. Stigma from God was measured in an 
indirect manner. It is possible that respondents were responding to religious 
commitments and not perceived stigma. 
Additional questions were asked to determine self-stigmatization and 
stigmati zation by others. Neither of these analyses was statistically significant. An 
exami nation of the raw data revealed some interesting trends. In terms of feeling 
stigmatized by se lf, the majority of the respondents felt moderately or strongly 
stigmati zed. Compl iant patients had a bimodal distribution, with one third of the 
respondents reporting little or no se lf-stigma. Given the trends in the data, it is likely that 
given a larger sample size, the differences would have been more noticeable. The data on 
feeling stigmatized by others formed an interesting contrast to self-stigma. One half of 
the respondents moderately or strongly agreed they felt stigmatized by others. For the 
noncompliant group, there was a group of virtually the same size who moderately to 
strongly disagreed about feeling stigmatized. This group who did not feel stigmatized is 
somewhat puzzling. They are not consistent with the literature, which would seem to 
make them more likely to take their medication. 
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Montano ( 1994) reported that stigma is associated wi th depression. Most 
fam ilies (with a depressed member) report that there is a stigma attached to depression 
(Montano). [n addition, education about depression helps to alleviate stigma. It may be 
that families in smaller communities have less access to stigma-allaying education. Guilt 
and shame (the emotions that may follow stigma) are feelings reported by depressed 
persons. Because guilt and shame respo nses are debilitating traits (Zukerman, 1995), 
humans must resolve guilt and shame to develop direction and purpose in li fe (Cole & 
Cole, 1993). It may have been that a group of these women had resolved these issues and 
therefore felt no stigma. 
The fifth null hypothesis was: patients who strongly agree that depress ion has 
had a negati ve effect on their family/social support systems are no more likely to 
discontinue antidepressant medication use than patients who di sagree that depression has 
had a negative effect on the ir family/socia l support systems. Whi le stati stical 
signifi cance was not obtained, the trend shows that women who discontinued their 
medication reported more symptoms in their close relationships and social support than 
those women who contmued their medtcation. Women who discontinued their 
medication also scored above the cutoff leve l on the social role and interpersonal 
relationships components of the OQ tm_ 45.2. The scores above the cutoff level indicate 
significant levels of problems in these areas. This is consistent with the previous 
hypotheses that the women were feeling stigmatized. It is reasonable to assume that 
women who did not take their medication experienced increased negative effects in their 
fami ly and socia l support systems. 
The results of this study are not statistically different, but the differences are 
clinically significant (Jacobson & Fol lette, 1984). Women who did not continue their 
medication were above the clinical cutoffs for both interpersonal and social role 
subscales . The cutoff scores can be helpful as they distinguish between distressed and 
nondistressed people in the areas of measurement. Thus the women in the medication 
noncompliant group fall in the clinically distressed range, while the women in the 
medication compliant group wou ld be classified as nondistressed. 
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The literature clearly indicates that depression is associated with relationship 
problems. This may occur because depressed people are often treated in ambivalent 
(sympathetic and hostile) ways (Baucom & Epstein, 1990). The problem is increased by 
the fact that depressed persons find it difficu lt or impossible to recover without help 
(Baucom & Epstein). The depressed person needs support to recover but Coyne ( 1987) 
has reported that depressed persons and their spouses are often conflictual and overtly 
hostile . Baucom and Epstein ( 1990) added that a circular pattern tends to deve lop in 
these families: the negativity of the depressed person elicits hostility/withdrawal from 
the partner, which causes more depression in the depressed member. Thi s process may 
be accentuated if the women do not take their medications. 
In summary, the women in the sample are distressed whether they continue their 
medications or not. In addition, most experience side effects and feel stigmatized. The 
general conclusion is that results were consistent with the literature even though results 
were not statisticall y significant. 
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Implications for Therapy 
Although levels of statistical significance were not reached with the null 
hypotheses, trends from the data present useful information for the practice of marriage 
and family therapy. The following are implications for the practice of marriage and 
family therapy: First, the literarure suggests that there is a beneficial effect of 
psychotherapy in connection with depression (Coyne, 1987; Hirschfeld, 1994); thus the 
combinati on of medication and psychotherapy is efficac ious. The data from this srudy 
show that only a small num ber of the women were receiving psychotherapy. This is 
critical , as Hirschfeld ( 1994, p. 337) has stated, "Psychotherapy plays a critical function in 
the long-term treatment of depression. Patients with depression, espec ially long-standing 
or recurrent depression, often have seri ous marita l, familial, social, and occupational 
problems that have been exacerbated by their illness." In addition, Law and Crane (2000) 
reported that people receiving marriage and family therapy services are less likely to need 
health care services. Thus the first recommendation is that therapists and doctors need to 
be more collaborative when treating depressed cl ients. 
Secondly, the research also acknowledges that compliance with antidepressant 
medication is a problem and suggests that the combination of psychotherapy and 
medication is efficacious. An obvious benefit is that the therapi st can reinforce the 
education the doctors and pharmac ists provide. 
This srudy showed that patients have and react to severe symptoms of depression, 
side effects , stigma, and negati ve effects on family/socia l support system, despite 
medication education. It also shows that the patients who were most depressed had the 
lowest degree of compliance with medication. The therapists can encourage medication 
compliance while helping reduce the impact on the family. 
A third implication is related to the assessment of depression. This assessment 
can be expanded by increasing the interaction between practitioner and therapist. The 
majority of the practitioners in thi s study want to know what more can be done to help 
treat depression. David Beckstead, M. D., a referring physician, believes that most 
patients are not clinically depressed but are suffering from being overwhelmed by life, 
which is not resolved by antidepressant medica tion (personal communication, April 7, 
1998). Receiving help for life issues falls within the realm of therapy, which can be an 
excellent resource for not only the health professional but also the patient. 
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From a medical standpoint, depression is treated in the following ways: The 
psychiatrist who participated in th is study, James Kirby, M.D., evaluates his clients and 
prescribes medication for depression and the associated side effects. Dr. Kirby continues 
to monitor patient medication in conjunction with a referral to psychotherapy. His 
approach combines medication and therapy. The physicians and physician assistants 
report they are being updated regularly concerning the pharmaceutical aspects of 
depress ion. They report a sizeable patient load with depression concerns. Their time is 
spent diagnosing, prescribing, and monitoring medication for depression and they can 
benefit from assistance with the concerns psychotherapy addresses. Psychotherapy is 
designed to address stigma, negative effects on family/support systems, and coping 
strategies for depression and its side effects. The psychotherapy mode l advocates 
integrating the following elements within three areas: (l) basic endowment: biogenetic, 
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family history, family environment, social background; (2) developmental Processes: 
social context, interpersonal/cognitive, mood, temperament; and (3) mediators: stressors, 
personal resources, social resources (Kupfer & Frank, 1998). The ideal alliance is a 
partnership between physician and therapist. The specific psychotherapy treatment 
approach suggested by the American Psychiatric Association (2000) is to evaluate for 
severiry of depression to determine any need for medication. With or without medication 
psychotherapy is recommended for symptom relief. 
Limitations 
The major limitations of this study are its small and unrepresentative sample. 
Medical practitioners agreed to gather data for this study to help find ways to alleviate 
the medication compliance problem. The practitioners and office staff were generous in 
this offer and anticipated knowing the results of this srudy. However, it was difficult for 
the medical office staff to gather data as it appears that they were already functioning at 
maximum capaciry. Each office was given 25 questionnaires and it was anticipated that 
150 rerurned questionnaires could be obtained. Over a 6-month period oniy 36 
questionnaires were rerumed. 
It also should be noted that volunteers who completed questionnaires may be 
different from the general population suffering from depression. It is possible that 
women who participated were so distressed they utilized their health care options more 
than other women, and hence the sample was skewed in a negative or more distressed 
direction. Conversely, participants might have been less distressed than the general 
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population. The extent of sample bias cannot be determined and thus it cannot be figured 
into the study results. 
The biggest problems with low n are that the sample is not big enough to examine 
larger patterns and to fac ili tate effective statistica l testing. Thus the low n precluded use 
of more advanced statistical methods to examine how the different factors worked 
together. 
Recommendations 
In retrospect, it appears that more data may have been co llected if the researcher 
had ~ol lected the data in each medical office. The time spent by the researcher 
monitoring the data collection over a period of 6 months could have been better spent in 
concentrated periods gathering data in each office. 
There is always a concern with measurement validity. In this case the 
questionnaire may not be a true reflection of the participant. It may be that the 
participants do not interpret questions consistently because o f interpretation variations or 
misunderstandings. It may be better to have a trained data collector administer the 
questionnaire. 
In summary, the purpose of this study was to investigate medication compliance 
or noncompliance in the context of the five variables (severity of symptoms, medical side 
effects, medication education, perceived st igma, and effects on family/social support 
system) to add to the body of knowledge concerning depression. Within this purpose was 
the researcher's goa l to raise awareness of the efficacy of using marita l and family 
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therapy as a conjunct to the medical treatment of depression. Within the limited scope of 
thi s study, it appears interest and awareness concerning therapy were increased among 
the medical practitioners and staff who participated. 
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SUBJECT: Correlates of Anti-depressant Use Among Women 
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review by the Institutional Review Board. The IRB appreciates researchers who recognize the 
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subject to confidentiality, privacy or withdrawal at any time from the research activities. 
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of Health and Human Services (DHHS) regulations for the protection of human research 
subjects, 45 CFR Part 46, as amended to include provisions of the Federal Policy for the 
Protection of Human Subjects, June 18, 1991. 
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risk of criminal or civil liability or be damaging to the subjects' financial standing, 
employability, or reputation. 
Your research is exempt from. further review based on exemption number 2. Please keep 
the committee advised of any changes, adverse reactions or termination of the study. A yearly 
review is required of all proposals subxnitted to the IRB. We request that you advise us when 
this project is completed, otherwise we will contact you in one year from the date of this letter. 
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Utah State OEPARTMlNT 01 FAM.Il.Y ANO HU#MN OE'VU.OPMEHT """'" d f omlly Ulo 
UNIVERSITY 1905 Unlwnlty II~ !"hone: (150 1) 797· 1501 \.at.&n VT f.4J2l·no5 FAX! ~1) 7'97·3&45 
INFORMED CONSENT 
Dale: ____ _ 
Scot M Allgood, Pb.D andPamcla:11IIIon; B.S., iil1hc Family IIJd·Huma.trDcvclopmcllt 
Department at Utah State Univenity ""' CODductin& a masten thcois =carch study to find more 
about how women usc lllltidepn:ssant medication prescribed by their physician and what 
inflw:nccs thcoe decisions. You have been asked to lake part in this =ch because you have 
been prescribed an antidepressam medication. Tbae will be approximal.cly 40 participents a.t 
this site. We will usc your answcrs to help us find ways to decrease the negative cooscqucnces 
associated with lllltidcpr<ssaut medication usc. 
If you agree to be in this study, you will be asked to answer questions about your usc of 
prescribed medication ant,! how you acncrallY set along in life. Please do not put your name on 
your questionnaire. They will not be kept with your pati:nt file, but w-JJ be ;lcposiled. by you, m 
a locked filo box. thc:zeby insuring your confidentiality. Puticipation in this study may involve 
some psychologi~ di3comfon. If you have concerns please talk to your physician about it 
today during your appoin.tmcnt. 
There may or may not be any dinx:t bcm:fit to you from these procedures. The 
invcotigator, however, may learn moro about how women usc antidepressant medication 
prescribed by their physician, and what things inflw:ncc that decision. This study may benefit 
medicaVpsychologicallcnowlcdgo and othcn now and in tho future. 
A member of your physician'• office staff has explained this study to you and answered 
your questions. If you havo other qucotions or research-related problems, you may reach 
Professor Scot M Allgood a.t ( 43$) 1S3-S89S. Puticipation in =ch is entirely voluntary. 
You may refuse to puticipate or withd.taw at any tiine without any·conscquoncc. 
Your results will be~ confidential according to federal and state laws. There will be 
no way to link your name with your questionnaire. Only the investigaton will have ..:ccs to the 
data, and it will be ~ in a locked filo cabinet when picked up from your doctor. 
The ln•titutional Review Board (IRB) for the protection of human subjccu at Utah State 
University has reviewed and approved this =ch project. Your rctum of this questionnaire 
implico that you UDd=tand the above information and to porticipate · this project. 
-::;~~~~ ' 
Scot M. Allgood, Pb.D:=;ll! Investigator 
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Medication Usage Questionnaire 
Many women have trouble s~aying on their antidepressant medications. Please complete the follow ing 
survey to help us understand why. These two surveys (Medication usage Questionnaire and OQ-45) are 
confidenti al so do not put your name on them. T hey will no t be attached to yo ur pa tient fil e. Certain 
issues have been included because they are thought to influence how people use their medication. Please 
co mplete t he followin g items by fillin g in the blank or writing th e a nswer. 
I. Your age: __ 
2. N umber of children ever born: 
3. Total annual household income:$ _ _ _ 
Please circle answer s th a t make the mos t sense, or a r e th e most true fo r yo u. 
4. Education: years com~leted (high school = 12) ____________ _ 
5. Your current marita l status: 
Married Divorced Separated Never been married 
6 . Have you had any problems with finances o r medical insurance since you were diagnosed 
with depress ion? 
Yes No 
7. Aie you currently seeing a psychologist or therapist for your depression? 
Yes No 
8. If you are seeing a psychologist or therapist, is the combination of medication and therapy 
helping you dea l with your depress ion related concerns? 
Yes No 
9. If you are nor receiving therapy for your depression, would you like information on available 
resources? 
Yes No 
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10. [have experienced a 10% weight gain since taking my antidepressant. 
Yes No 
II. I have experienced a I 0% weight loss since taking my antidepressant. 
Yes No 
12. How many times a week do you take your antidepressant medication? 
Zero One Two Three Four Five Six Seven 
t3. When you don't take your antidepressant medication, what is the reason? 
Forget Cost of refill prescription Side effects Other (please _______ _ 
14. Have you discon tinued your an tidepressant medication on your own? 
Yes No Please explain ----------------
15 . How did your doctor prescribe your medication to be taken? 
Please explain-----------------------------
16. Have you had follow-up appointments with your doctor for your an tidepressant medication? 
Yes No 
17. ffyou are not taking your antidepressant medication seven days/week, how are you taking it? 
6 days/week 
3 days/week 
As needed 
5 days/week 
2 days/week 
4 days/week 
I day/wk 
Other ____________________ _ 
18. When you were prescribed antidepressant medication, how well did your physician explain the 
properties of the medication and what you could expect? 
Very detailed Detailed Not detailed No explanation I don't remember 
19. When you filled your prescription for an tidepressant medica tion, how well did your pharmacist 
explain the medication and what you could expect? 
Very detailed Deta iled Not detailed No explanation I don't remember 
20. Did your physician or pharmacist inform you about the side effects of your medication? 
Very detailed Detailed Not detailed No explanation I don't remember 
21. When you filled your prescription for antidepressant medication, how thoroughly did you read the 
written material about side effects? 
Read thoroughly Read pretty well Read a little Did nor read 
I don't remember 
For each statement there are six (6) possible responses: Strongly agree (I); Moderately agree (2); 
Slightly ai,'Tee (3); Sl ightly disagree (4); Moderately disagree (5); and Strongly disagree (6). 
Please circle answers that make the most sense, or are most true for yo u. 
4 
4 
4 
4 
4 
4 
4 
22. I have problems with my own low sexual interest or desire that 
seems to be related to antidepressant medication . 
23. I have problems with sexual functioning that seems to 
be related to antidepressant medication. 
24. Someone in my family feels there is a stigma attached to 
depression. 
25 . I feel there is a stigma attached to depression. 
26. My depression has had a negative effect on my family and/or 
others. 
27. I am satisfied with my marriage? 
28. I am sat isfied with my family? 
29. My faith involves all of my life. 
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4 6 
4 
30. One should seek Divine guidance when making every important 
decision. 
3 1. In my life, I experience the presence of the Divine. 
32. My faith sometimes restricts my actions. 
33. Although I am a religious person, I refuse to let religious 
considerations influence my everyday affairs. 
34. My religious beliefs under lay my whole approach to life. 
35. From your experience what could providers (therapists, doctors, or pharmacists) do that would help 
people deal with depressive symptoms? (Respond in the space below) 
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